CA2838824A1 - Modulation of pancreatic beta cell proliferation - Google Patents

Modulation of pancreatic beta cell proliferation Download PDF

Info

Publication number
CA2838824A1
CA2838824A1 CA2838824A CA2838824A CA2838824A1 CA 2838824 A1 CA2838824 A1 CA 2838824A1 CA 2838824 A CA2838824 A CA 2838824A CA 2838824 A CA2838824 A CA 2838824A CA 2838824 A1 CA2838824 A1 CA 2838824A1
Authority
CA
Canada
Prior art keywords
seq
agent
peptide
functional portion
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2838824A
Other languages
English (en)
French (fr)
Inventor
Douglas A. Melton
Peng YI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of CA2838824A1 publication Critical patent/CA2838824A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
CA2838824A 2011-06-10 2012-06-10 Modulation of pancreatic beta cell proliferation Abandoned CA2838824A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161495868P 2011-06-10 2011-06-10
US61/495,868 2011-06-10
US201261613856P 2012-03-21 2012-03-21
US61/613,856 2012-03-21
PCT/US2012/041804 WO2012170977A1 (en) 2011-06-10 2012-06-10 Modulation of pancreatic beta cell proliferation

Publications (1)

Publication Number Publication Date
CA2838824A1 true CA2838824A1 (en) 2012-12-13

Family

ID=47296512

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2838824A Abandoned CA2838824A1 (en) 2011-06-10 2012-06-10 Modulation of pancreatic beta cell proliferation

Country Status (7)

Country Link
US (1) US20140303078A1 (enExample)
EP (1) EP2717924A4 (enExample)
JP (1) JP2014523871A (enExample)
CN (1) CN104039357A (enExample)
AU (1) AU2012267492A1 (enExample)
CA (1) CA2838824A1 (enExample)
WO (1) WO2012170977A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140050720A1 (en) 2012-01-09 2014-02-20 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
EP2802601B1 (en) 2012-01-09 2019-11-13 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
EP2943512A4 (en) * 2013-01-11 2016-06-01 California Inst Biomedical Res BOVINE FUSION ANTIBODY
CA2904198A1 (en) * 2013-03-15 2014-09-18 Universite De Geneve Use of insulin signaling antagonists, optionally in combination of transfection of non-beta cells, for inducing insulin production
JP6687520B2 (ja) 2013-07-18 2020-04-22 トーラス バイオサイエンシズ リミテッド ライアビリティ カンパニー 極めて長い相補性決定領域を有するヒト化抗体
US9322037B2 (en) * 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
CN106536552A (zh) * 2014-03-12 2017-03-22 生物控股有限公司 能够拮抗胰岛淀粉样多肽(IAPP)诱导的β细胞损伤和葡萄糖耐量受损的新的化合物
CA2954082A1 (en) * 2014-10-03 2016-04-07 Ngm Biopharmaceuticals, Inc. Methods and compositions for treatment of conditions associated with elevated triglycerides
TW201713690A (zh) * 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
WO2017062363A1 (en) * 2015-10-05 2017-04-13 Joslin Diabetes Center Methods of use of betatrophin
US11161891B2 (en) 2015-12-09 2021-11-02 The Scripps Research Institute Relaxin immunoglobulin fusion proteins and methods of use
EP3749691A4 (en) 2017-11-10 2021-10-27 NGM Biopharmaceuticals, Inc. ANGPTL8 LIAISON AGENTS AND THEIR METHODS OF USE
US12508428B2 (en) 2023-01-26 2025-12-30 Medtronic, Inc. Respiratory-based cardiac remodeling pacing therapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070055056A1 (en) * 1997-03-07 2007-03-08 Rosen Craig A 251 human secreted proteins
JP2001512005A (ja) * 1997-08-01 2001-08-21 ジェンセット 内胚葉において発現する分泌タンパク質の５’ｅｓｔ
US6875741B2 (en) * 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
US20070203083A1 (en) * 2003-06-13 2007-08-30 Mootha Vamsi K Methods Of Regulating Metabolism And Mitochondrial Function
AU2006223579A1 (en) * 2005-03-11 2006-09-21 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
JP2009511446A (ja) * 2005-10-05 2009-03-19 ノボ・ノルデイスク・エー／エス インスリンレセプターアンタゴニストと、関連した組成物、使用及び方法
CN101130768B (zh) * 2006-08-22 2010-05-12 复旦大学 核苷酸分子sr1b及其在制备抗糖尿病药物中的应用
NZ575804A (en) * 2006-09-13 2012-01-12 Univ Columbia Undercarboxylated/uncarboxylated osteocalcin increases beta-cell proliferation, insulin secretion, insulin sensitivity, glucose tolerance and decreases fat mass
US20090232893A1 (en) * 2007-05-22 2009-09-17 Bader Andreas G miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION

Also Published As

Publication number Publication date
JP2014523871A (ja) 2014-09-18
WO2012170977A1 (en) 2012-12-13
EP2717924A1 (en) 2014-04-16
AU2012267492A1 (en) 2014-01-09
CN104039357A (zh) 2014-09-10
US20140303078A1 (en) 2014-10-09
EP2717924A4 (en) 2015-04-22

Similar Documents

Publication Publication Date Title
US20140303078A1 (en) Modulation of pancreatic beta cell proliferation
JP7807359B2 (ja) 新規なｉｇｆｒ様レセプター及びその使用
US20050020519A1 (en) Modulation of insulin-regulated aminopeptidase (irap)/angiotensin iv (at4) receptor activity
CN103648531A (zh) 用于预防或治疗代谢综合症的方法
EP3151855B1 (en) Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies
Pittenger et al. Intramuscular injection of islet neogenesis-associated protein peptide stimulates pancreatic islet neogenesis in healthy dogs
US20170157110A1 (en) Methods for inducing insulin production and uses thereof
WO2013102209A1 (en) Glypican-4 based compositions and methods for treating and diagnosing insulin resistance
CN106030311B (zh) 线粒体融合蛋白的方法和用途
KR20120090931A (ko) 심혈관 및 대사성 질환, 예컨대 제2형 당뇨병의 치료를 위한 ｎｋｇ2ｄ 억제제의 용도
US10980857B2 (en) Treatment with GDF11 prevents weight gain, improves glucose tolerance and reduces hepatosteatosis
TWI359271B (en) Pharmaceutical composition for insulin resistance
US11999776B2 (en) IGFR-like 2 receptor and uses thereof
JP2016513968A (ja) Ｏ−結合ｎ−アセチルグルコサミントランスフェラーゼを標的する組成物及び方法並びに創傷治癒を促進する組成物及び方法
JP2023509222A (ja) 糖尿病治療用の薬物の製造におけるｇｐ７３阻害剤の使用
US12583928B2 (en) Antibodies against IGFR-like receptor and uses thereof
US20260139016A1 (en) Methods and compositions for treating metabolic disorders
CN112673019A (zh) 卵泡抑素的抑制
Lee Insulin-Independent Regulation of Type 1 Diabetes via Large Brown Adipocyte-Secreted Proteins and the Novel Glucagon Regulator, Nidogen2
WO2008012932A1 (en) Insulin resistance reducer
Lam AIBIS abstracts
HK40002382B (en) Treatment with gdf11 prevents weight gain, improves glucose tolerance and reduces hepatosteatosis

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20180612